About Xenogen
Xenogen is a company based in Alameda (United States) founded in 1994 was acquired by Taconic in December 2009. Xenogen has raised $47 million across 2 funding rounds from investors including Chevron, Abingworth and Taconic Biosciences. Xenogen operates in a competitive market with competitors including Bio Rad, Siemens Healthineers, Merck, Quanterix and Biocare Medical, among others.
- Headquarter Alameda, United States
- Stage Public
- SectorsHealthcare
- Website xenogen.com
- Acquired by Taconic (Dec 2009)
- Legal Name Xenogen Corporation
Funding Insights of Xenogen
Xenogen has successfully raised a total of $47M across 2 strategic funding rounds. The most recent funding activity was a Series C round of $22 million completed in July 2003. This substantial capital infusion reflects strong investor confidence in the company's business model, growth potential, and market opportunities. The funding enables strategic expansion, product development, market penetration, and operational scaling to drive long-term value creation and competitive advantage.
- Total Funding $47M
- Total Rounds 2
- Last Round Series C — $22M
- First Round $25M
(Jun 2001)
- Investors Count 4
All 2 funding rounds of Xenogen with amounts and investors; the two latest post-money valuations are shown, the rest are part of the premium plan.
| Date | Amount | Transaction Name | Valuation | Lead Investors | Investors |
|---|---|---|---|---|---|
| Jul 2003 | $22M | Series C | – | – | |
| Jun 2001 | $25M | Series B | – | – |
6 investors in total: 6 institutional.
Investors in Xenogen
Xenogen has secured backing from 6 investors, including venture fund and institutional investors. Prominent investors backing the company include Chevron, Abingworth and Taconic Biosciences.
| Investor | Description | Founded Year | Domain | Location |
|---|---|---|---|---|
Early stage venture capital firm investing in US | 1973 | abingworth.com | London, United Kingdom | |
A biotechnology venture capital firm investing in innovative science. | – | srone.com | - | |
Provider of wealth management services | 1796 | lombardodier.com | Geneva, Switzerland | |
Chevron Corporation is engaged in global energy production and sustainability. | 1879 | chevron.com | United States | |
Drug discovery, research, and diagnostics are provided to biopharma firms. | 1995 | caliperls.com | Hopkinton, United States | |
Animal models and laboratory services are provided for research needs. | 1952 | taconic.com | Hudson, United States |
Investor details for Xenogen
The complete investor list, round-by-round participation and investor portfolios require an active premium plan.
- Complete investor list
- Round participation
- Investor portfolios
- Co-investor network
Verified entity values are shown only after access is granted.
Timeline of Xenogen
6 dated milestones of Xenogen across 15 years, from founding to its latest funding, stage changes and deals.
- Founded Xenogen is founded.
- Funding First funding round of $25.0M.
- Funding Latest funding round, Series C, of $22.0M.
- IPO Lists on the stock exchange (IPO).
- Exit Acquired by Caliper Life Sciences.
- Exit Acquired by Taconic.
Competitors of Xenogen
Xenogen operates in a dynamic and competitive business environment, facing competition from various established players and emerging companies in the market. The competitive landscape includes prominent companies such as Bio Rad, Siemens Healthineers, Merck, Quanterix and Biocare Medical, among others.
| Company Name | Domain | Founded | HQ Location | Total funding | Employees | Description |
|---|---|---|---|---|---|---|
| bio-rad.com | 1952 | Hercules, United States | – | 10 | Portfolio of products and services for life science research and clinical diagnostic markets | |
| siemens-healthineers.com | 1847 | Erlangen, Germany | – | 66,000 | AI-based medical diagnostics are developed for healthcare applications. | |
| merckgroup.com | 1668 | Darmstadt, Germany | – | 922 | Merck is engaged in science and technology solutions globally. | |
| quanterix.com | 2007 | Cambridge, United States | $99.5M | 141 | Assay kits for ultra-sensitive biomarker detection are developed. | |
| biocare.net | 1997 | Concord, United States | $85M | 161 | Primary antibodies and instruments for immunohistochemistry are manufactured. | |
| biolifesolutions.com | 1987 | Bothell, United States | – | 685 | Tissue hypothermic storage and cryopreservation freeze media are developed. | |
| apbiocode.com | 2008 | Santa Fe Springs, United States | $20.29M | 66 | Assay kits and instruments for in vitro diagnostics are developed. | |
| telesisbio.com | 2013 | San Diego, United States | $25M | – | Online platform offering life sciences reagents and kits |
Detailed competitors of Xenogen
The full competitor set, operating metrics and side-by-side benchmarks require an active premium plan.
- Full competitor set
- Operating metrics
- Benchmarks
- Competitive positioning
Verified entity values are shown only after access is granted.
Web traffic of Xenogen
Websites that share an audience with Xenogen (xenogen.com).
Websites whose visitors overlap most with Xenogen. Affinity shows how closely the audiences match.
| Website | Domain | Audience affinity | Monthly visits | Global rank | Profile |
|---|---|---|---|---|---|
| taconic.com | 90% | 49.8K | #707,498 | View details | |
| macrogen.com | 77% | 181K | #169,305 | View details |
Similar companies to Xenogen
10 companies that operate in the same segment as Xenogen (Life Sciences Platforms & Tools), ranked by their profile score on The Company Check.
| Company | Description | Founded | Location | Total funding | Revenue | Employees |
|---|---|---|---|---|---|---|
Medidata is recognized as a leading provider of SaaS solutions for clinical research. | 1999 | New York, New York, United States | USD 41.5 M | – | – | |
AI-based solutions for health management are provided. | 2015 | Dallas, Texas, United States | USD 2.8 B | – | – | |
Nanopore-based electronic systems for single-molecule analysis are developed. | 2005 | Oxford, Oxfordshire, United Kingdom | USD 1.3 B | USD 301.49 M | 1,480 | |
Real-world health data is provided for research and decisions. | 2012 | Menlo Park, California, United States | USD 259.16 M | – | – | |
Genetically modified cell lines are developed using AAV gene-editing platform. | 2007 | Cambridge, Cambridgeshire, United Kingdom | USD 46.29 M | – | – | |
Biological reagents and antibodies are developed for life science research. | 1998 | Cambridge, Cambridgeshire, United Kingdom | USD 78.8 M | – | – | |
Electron microscopy services and microanalysis instruments are provided. | 1956 | Waltham, Massachusetts, United States | – | USD 44.56 B | 125,000 | |
Novel therapeutics are discovered using an AI-enabled drug platform. | 2013 | New York, New York, United States | USD 456.66 M | USD 74.68 M | – | |
A platform for sharing and accessing academic research papers is provided. | 2008 | San Francisco, California, United States | USD 58.4 M | – | – | |
Developer of molecular diagnostic testing solutions | 1996 | Sunnyvale, California, United States | USD 19.1 M | USD 54.88 M | 208 |
Unlock complete access to The Company Check
Get unrestricted viewing across everything we track — from companies and brands to investors, funding rounds, acquisitions, financials, and more.
- Unlimited viewing on all profiles Companies, investors, financials, funding, acquisitions & directors
- Full access to every database India & global coverage, advanced filters and rich profile details
- Always-on access from your team account Single premium plan for everything you see on the portal
Frequently Asked Questions about Xenogen
Xenogen was founded in 1994 and raised its 1st funding round 7 years after it was founded.
Xenogen is headquartered in Alameda, United States. It is registered at Alameda, California, United States.
Xenogen is a funded company, having raised a total of $47M across 2 funding rounds to date. The company's 1st funding round was a Series B of $25M, raised on Jun 2001.
Xenogen was founded in 1994 in Alameda, United States, within the biotechnology sector. In vivo target and compound evaluation services are offered, alongside the design, production, and phenotyping of genetically modified animal models, particularly rodents. These operations support drug development processes for pharmaceutical and research entities across the United States.
Xenogen's top competitors include Biocare Medical, Merck and Siemens Healthineers.
Xenogen has 6 investors. Key investors include Chevron, Abingworth, Taconic Biosciences, Lombard Odier, and Caliper Life Sciences.
Xenogen operates through Xenogen Corporation.
Yes. Xenogen was acquired by Taconic in December 2009.